Imlygic (talimogene laherparepvec) / Amgen  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imlygic (talimogene laherparepvec) / Amgen
NCT02173171 / 2015-003196-29: Registry Study for Talimogene Laherparepvec

Completed
N/A
185
Europe, Canada, US, RoW
Information collection, Q3M Information collection
Amgen
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
09/21
09/21
NCT02910557: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Recruiting
N/A
300
Europe, US, RoW
Amgen
Melanoma, Herpetic Infection
01/38
01/38

Download Options